Magnetar Financial LLC
Institutional investor · Portfolio as of Q2 2019
Top Holdings435 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
WELLCARE HEALTH PLANS INC | 912,876 | $260.2M | 5.2% | — | — | 1 qtr | New 95 |
FIRST DATA CORP NEW | 8.5M | $230.4M | 4.6% | — | — | 1 qtr | New 85 |
VANTIV INC | 1.9M | $228.8M | 4.6% | — | — | 1 qtr | New 85 |
TOTAL SYS SVCS INC | 1.7M | $224.1M | 4.5% | — | — | 1 qtr | New 85 |
WABCO HLDGS INC | 1.7M | $220.8M | 4.4% | — | — | 1 qtr | New 85 |
RED HAT INC | 1.1M | $212.2M | 4.2% | — | — | 1 qtr | New 85 |
TRIBUNE MEDIA CO | 4.3M | $198.7M | 4.0% | — | — | 1 qtr | New 85 |
CYPRESS SEMICONDUCTOR CORP | 8.5M | $189.3M | 3.8% | — | — | 1 qtr | New 84 |
MELLANOX TECHNOLOGIES LTD | 1.7M | $187.8M | 3.8% | — | — | 1 qtr | New 84 |
CELGENE CORP | 1.9M | $174.2M | 3.5% | — | — | 1 qtr | New 84 |
TABLEAU SOFTWARE INC | 1M | $173.3M | 3.5% | — | — | 1 qtr | New 84 |
ALLERGAN PLC | 966,272 | $161.8M | 3.2% | — | — | 1 qtr | New 84 |
| 13.2M | $156.1M | 3.1% | — | — | 1 qtr | New 84 | |
| 23.5M | $154.6M | 3.1% | — | — | 1 qtr | New 84 | |
| 3.2M | $148.4M | 3.0% | — | — | 1 qtr | New 78 | |
VERSUM MATLS INC | 2.8M | $143.3M | 2.9% | — | — | 1 qtr | New 78 |
ARKO Petroleum Corp. | 1.7M | $123.5M | 2.5% | — | — | 1 qtr | New 78 |
ADVANCED DISP SVCS INC DEL | 3.7M | $119.5M | 2.4% | — | — | 1 qtr | New 78 |
FINISAR CORPATION | 5.1M | $117.4M | 2.4% | — | — | 1 qtr | New 78 |
SPARK THERAPEUTICS INC | 885,199 | $90.6M | 1.8% | — | — | 1 qtr | New 68 |
Magnetar Financial LLC manages $5B across 435 positions as of Q2 2019. Top holdings: WCG (5.2%), FDC (4.6%), WP (4.6%). Fund DNA: Diversified Scout. HoldingsIntel Rating: 3/5.0.
Active quarter - 427 new positions, 0 exits, 0 increased. Top move: WCG (NEW, conviction 95). Portfolio: $5.0B across 435 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer